
Leica Microsystems is owned by Danaher Corporation (NYSE: DHR), a global science and technology innovator headquartered in Washington, D.C. Danaher acquired Leica Microsystems in 2005 as the foundation of its Life Sciences segment, which reported FY2025 revenue of $7.33 billion. Leica Microsystems is headquartered in Wetzlar, Germany, and is a market leader in compound and stereo microscopy, digital microscopy, confocal laser scanning microscopy, electron microscopy sample preparation, and surgical microscopes. Danaher reported FY2025 total revenue of $24.6 billion.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Leica Microsystems | Danaher Corporation | Wholly owned |
Leica Microsystems traces its origins to 1849 when optician Carl Kellner founded an optical workshop in Wetzlar, Germany. The company has been widely recognized for its optical precision and innovative technology since its inception as a family business in the nineteenth century.
Over more than 170 years, Leica Microsystems has evolved from a small optical workshop into a global leader in microscopy and scientific instrumentation. The company has pioneered numerous innovations in optical microscopy, imaging systems, and sample preparation technologies.
In 2005, Danaher Corporation acquired Leica Microsystems, making it the foundation of its newly established Life Sciences segment. Under Danaher's ownership, Leica Microsystems has expanded its product portfolio through organic development and strategic acquisitions, adding capabilities in digital microscopy, AI-powered image analysis, and fluorescence imaging.
Today, Leica Microsystems has six major plants and product development sites around the world, is represented in over 100 countries, has sales and service organizations in 20 countries, and maintains an international network of distribution partners.
What does Danaher Corporation own?
Danaher owns approximately 15 operating companies across three segments. In Biotechnology, it owns Cytiva and Pall Corporation. In Life Sciences, it owns Leica Microsystems, Molecular Devices, Integrated DNA Technologies, SCIEX, and Beckman Coulter Life Sciences. In Diagnostics, it owns Beckman Coulter Diagnostics, Cepheid, Radiometer, Leica Biosystems, and Masimo. It also owns environmental and applied solutions brands including Hach and Videojet.
Is Danaher Corporation publicly traded?
Yes. Danaher Corporation is publicly traded on the New York Stock Exchange under the ticker symbol DHR. The company is a component of the S&P 500 and is owned by institutional investors, mutual funds, and individual shareholders. There is no parent company or controlling shareholder.
Who founded Danaher Corporation?
Danaher was founded in 1969 by brothers Steven M. Rales and Mitchell P. Rales in Washington, D.C. The Rales brothers established the company as a diversified industrial conglomerate and built it into a global life sciences and diagnostics leader through decades of disciplined acquisitions and operational improvement.
Where is Danaher Corporation headquartered?
Danaher is headquartered in Washington, D.C., USA. The company's corporate offices are based in the Washington, D.C. metropolitan area, with operating companies and manufacturing facilities distributed across the United States, Europe, Asia, and the Americas.
How many brands does Danaher Corporation own?
Danaher owns approximately 15 operating companies across its three segments. These include well-known brands in life sciences and diagnostics such as Cytiva, Pall, Leica Microsystems, Beckman Coulter, Cepheid, Radiometer, and Masimo. The company also owns environmental and industrial brands including Hach and Videojet.
Who owns Danaher Corporation?
Danaher is an independent publicly traded corporation with no parent company. The company is owned by institutional investors, mutual funds, and individual shareholders who hold its NYSE-listed common stock. The Rales brothers remain significant shareholders and board members but do not hold a controlling stake. Major institutional holders include Vanguard Group, BlackRock, and State Street Corporation.
What were Danaher's recent financial results?
For FY2025, Danaher reported $24.6 billion in revenue and $3.6 billion in net earnings. In Q2 2026, revenue was $6.3 billion, up 5.5%, with net earnings of $870 million and adjusted EPS of $1.94, up 8.0%. The company raised its 2026 guidance to adjusted EPS of $8.45 to $8.60 and core revenue growth of 3.0% to 4.0%.
Has Danaher made major acquisitions recently?
In June 2026, Danaher completed the acquisition of Masimo Corporation for $9.9 billion, adding pulse oximetry and patient monitoring to its Diagnostics segment. In 2023, Danaher acquired Abcam for approximately $5.7 billion. The largest acquisition in company history was Cytiva (formerly GE Life Sciences) for $21.4 billion in 2016.
Leica Microsystems operates within Danaher Corporation's sustainability framework, which focuses on accelerating the power of science and technology to improve human health while reducing environmental impact. Danaher's sustainability priorities include product innovation for health improvement, operational efficiency, and responsible supply chain management.
Sustainable Manufacturing: Leica Microsystems' six major plants and product development sites implement sustainable manufacturing practices, including energy-efficient production processes, waste reduction programs, and responsible resource management. The company's German headquarters operates under strict European environmental regulations.
Product Innovation for Health: Leica Microsystems' products contribute to improving human health by enabling faster, more accurate diagnoses and helping reduce the time and cost needed to discover, develop, and deliver life-changing therapies. The company's AI-powered imaging tools and surgical microscopes directly support medical research and clinical applications.
Supply Chain Responsibility: As part of Danaher Corporation, Leica Microsystems adheres to Danaher's supply chain standards, which include supplier quality requirements, environmental compliance, and ethical sourcing practices across approximately 50 countries where Danaher operates.
Energy Efficiency: Leica Microsystems designs products with energy efficiency in mind, including LED illumination systems in microscopes that reduce energy consumption and heat generation compared to traditional light sources. The company's digital microscopy systems reduce the need for physical materials in research workflows.
Leica Microsystems has been recognized throughout its 170+ year history for optical precision, innovative technology, and contributions to scientific research and medical diagnostics.
EcoVadis Silver Medal (September 2025): Leica Microsystems was awarded the Silver Medal by EcoVadis, a globally recognized provider of business sustainability ratings. This prestigious distinction places Leica Microsystems among the top 15% of rated companies worldwide and affirms the company's commitment to responsible innovation, environmental stewardship, and inclusive growth. The award recognizes Leica Microsystems' comprehensive sustainability strategy and measurable progress across environmental, social, and governance dimensions.
Microscopy Today Innovation Award (July 2025): Leica Microsystems was honored with the prestigious 2025 Microscopy Today Innovation Award, presented by the Microscopy Society of America. The award recognized the company's groundbreaking SpectraPlex solution, a multiplexing technology integrated with the STELLARIS confocal microscope platform. SpectraPlex enables simultaneous detection of 15+ markers in a single round of staining and acquisition, eliminating the need for cyclic imaging and preserving precious tissue integrity.
Scientific Innovation Recognition: Leica Microsystems' products and technologies have received numerous awards from scientific societies and research institutions for advancing microscopy capabilities. The company's innovations in confocal microscopy, super-resolution imaging, and spatial biology have been acknowledged for transforming how scientists explore complex biological systems and develop new treatments.
Technology Leadership Awards: The company's microscopy solutions have received recognition for technological excellence and innovation in scientific instrumentation. Awards highlight Leica Microsystems' ability to develop cutting-edge imaging technologies that enhance research capabilities and enable new discoveries in life sciences, medicine, and materials science.
Research Partnership Recognition: Leica Microsystems has been acknowledged for successful partnerships with research institutions, universities, and pharmaceutical companies. These collaborations have resulted in joint publications, research breakthroughs, and technological advancements that demonstrate the company's commitment to supporting scientific progress.
Customer Satisfaction and Quality Awards: The company has received recognition for customer satisfaction, product quality, and technical support excellence. These awards reflect Leica Microsystems' commitment to providing reliable, high-performance microscopy solutions that meet the demanding requirements of research and diagnostic applications.
Environmental and Sustainability Leadership: Beyond the EcoVadis Silver Medal, Leica Microsystems has received recognition for its environmental initiatives and sustainability programs. The company's efforts in reducing carbon emissions, implementing sustainable manufacturing practices, and developing eco-friendly products have been acknowledged by environmental organizations and industry groups.
Industry Association Recognition: Leica Microsystems has received awards and recognition from various microscopy and scientific imaging associations for its contributions to advancing the field. These acknowledgments highlight the company's role in developing new technologies, setting industry standards, and promoting best practices in microscopy.
Danaher Corporation Achievement: As part of Danaher Corporation, Leica Microsystems benefits from the group's recognition as a leader in science and technology innovation. Danaher's overall performance and sustainability achievements reflect positively on Leica Microsystems' position within the scientific instrumentation market.
Leica Microsystems has maintained a relatively clean operational record throughout its history, with minimal major controversies or product recalls. As a manufacturer of scientific instrumentation rather than consumer products, the brand faces different types of challenges, primarily related to market competition, technological transitions, and the broader scientific research funding environment rather than safety or quality issues.
Market Competition and Technological Disruption: Leica Microsystems faces intense competition from other microscopy equipment manufacturers, including established competitors like Zeiss, Nikon, Olympus (Evident), and Thermo Fisher Scientific. The company must continuously innovate to maintain its market position, as demonstrated by its 2025 product launches in AI software, digital fluorescence microscopy, and upright microscope series.
Research Funding Dependency: As a provider of equipment primarily to research institutions, academic laboratories, and diagnostic companies, Leica Microsystems is sensitive to fluctuations in research funding, government research budgets, and academic institution spending patterns. The Life Sciences segment's flat revenue performance in FY2025 reflects this sensitivity.
Regulatory Compliance Complexity: Operating in the scientific instrumentation market requires compliance with complex regulatory frameworks, including medical device regulations, laboratory safety standards, and international trade requirements. The company's Mateo FL system includes FDA 21 CFR Part 11 compliance features, demonstrating commitment to regulatory standards.
Supply Chain and Manufacturing Challenges: Leica Microsystems relies on specialized components and precision manufacturing processes across its six global plants that can be subject to supply chain disruptions. The company must maintain extremely high quality standards while managing costs and lead times associated with precision instrumentation.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Danaher | USA | 1946 | Market leader | Global | All-ages |
Market Positioning: Leica Microsystems competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Danaher Corporation, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
GE HealthCare operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Pfizer Inc.
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
Pfizer operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Koninklijke Philips N.V.
Health technology brand owned by Koninklijke Philips N.V., a publicly traded Dutch company listed on Euronext Amsterdam (PHIA). Covers medical imaging, patient monitoring, and personal health products.
Philips operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Leica Microsystems which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
Alcon operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Herbalife Ltd.
Global nutrition and weight-management brand owned by Herbalife Ltd. and sold through independent distributors in more than 90 markets.
Herbalife operates independently without a large parent corporation.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.